Nu-Med Plus (NUMD) EBIT Growth (1y) (2013 - 2025)
Nu-Med Plus (NUMD) EBIT Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.54 Bn | 176.24 Bn | 6.27 Bn | -20.56% |
| 2 | Stryker | 129.03 Bn | 126.15 Bn | 3.81 Bn | 11.83% |
| 3 | Medtronic | 108.43 Bn | 99.21 Bn | 6.41 Bn | 30.43% |
| 4 | Boston Scientific | 68.74 Bn | 67.28 Bn | 3.61 Bn | 19.54% |
| 5 | Edwards Lifesciences | 48.34 Bn | 44.67 Bn | 1.29 Bn | 20.97% |
| 6 | Dexcom | 28.35 Bn | 27.24 Bn | 750.30 Mn | 90.95% |
| 7 | GE HealthCare Technologies | 28.07 Bn | 25.78 Bn | 1.98 Bn | -18.12% |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | 74.18% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | -5.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.02% |
| Sep 30, 2025 | 42.15% |
| Jun 30, 2025 | 35.04% |
| Mar 31, 2025 | 9.13% |
| Dec 31, 2024 | 83.20% |
| Sep 30, 2024 | -14.99% |
| Jun 30, 2024 | 30.48% |
| Mar 31, 2024 | 23.70% |
| Dec 31, 2023 | -765.44% |
| Sep 30, 2023 | 73.91% |
| Jun 30, 2023 | 60.27% |
| Mar 31, 2023 | 54.79% |
| Dec 31, 2022 | 94.31% |
| Sep 30, 2022 | 50.96% |
| Jun 30, 2022 | 76.96% |
| Mar 31, 2022 | 83.28% |
| Dec 31, 2021 | 77.78% |
| Sep 30, 2021 | 73.68% |
| Jun 30, 2021 | 72.14% |
| Mar 31, 2021 | -132.66% |